Atara Biotherapeutics Price Target Announced at $25.00/Share by Rodman & Renshaw

Dow JonesDec 20 21:11 · Ratings

Atara Biotherapeutics Analyst Ratings

BenzingaDec 20 20:59 · Ratings

Kyverna Therapeutics Picks Former Atara Bio, Kite Executives for Leadership Roles

MT NewswiresDec 14 05:50

Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive...

PR NewswireDec 8 01:33

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

BusinesswireNov 28 05:01

Atara Biotherapeutics Reports Q3 2024 Financial Progress

TipRanksNov 14 11:59